ClinicalTrials.gg
CompletedNCT00319267FUTURE-1Updated Feb 3, 2025

Bosentan in Children With Pulmonary Arterial Hypertension

A Phase 3 interventional study of Bosentan in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
2 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
10th of 18
36 · median 37
Started
2005
with 1 other
Phase 3
7 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 10th largest by enrollment, is one of 2 that started in 2005, is one of 7 in phase 3, and was the 5th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that in adults with PAH and to evaluate the tolerability and safety of a pediatric formulation of bosentan in this patient population.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • bosentan
  • children
  • pharmacokinetics
  • pulmonary arterial hypertension
04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed by the parents or the legal representatives.
  • Males or females >= 2 and \< 12 years of age.
  • Idiopathic PAH or familial PAH diagnosed by right heart catheterization (Clinical classification of pulmonary hypertension, Venice 2003).
  • World Health Organization (WHO) functional class II or III.
  • Oxygen saturation (SpO2) >= 88% (at rest, on room air).
  • PAH treatment-naïve patients or patients already treated with either:

    • Bosentan monotherapy
    • Intravenous epoprostenol monotherapy
    • Intravenous or inhaled iloprost monotherapy
    • Combination of bosentan and intravenous epoprostenol
    • Combination of bosentan and intravenous or inhaled iloprost.
  • All patients should start the study drug (bosentan pediatric formulation) at 2 mg/kg twice daily (b.i.d.), whether or not they were previously treated with bosentan.
  • PAH therapy stable for at least 3 months prior to Screening.
  • Stable treatment with calcium channel blockers, if any, for at least 3 months prior to Screening.
  • Patient's PAH condition stable for at least 3 months prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • PAH associated with conditions other than idiopathic or familial PAH.
  • Non-stable patients, e.g., history (in the last 3 months prior to Screening) of recurrent syncope, or signs and symptoms of non-compensated right heart failure.
  • Need or plan to wean patients from intravenous epoprostenol, or intravenous, or inhaled iloprost.
  • Body weight \< 4 kg.
  • Systolic blood pressure \< 80%, the lower limit of normal range, according to age and gender.
  • and/or ALT values > 3 times the ranges.
  • Moderate to severe hepatic impairment, i.e., Class B or C.
  • and/or hematocrit levels \< 75% of the lower limit of normal ranges.
  • Pregnancy.
  • Known intolerance or to bosentan or any of the .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Bosentan

    The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.

    Drug: Bosentan

Interventions

  • Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets

    Also known as: ACT-050088, Ro 47-0203

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve during a dose interval (AUCt) for bosentan

    AUCt was assessed at steady state (i.e., after at least 2 weeks of treatment with a same dose of the study drug) over 12 hours .

    Time frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of bosentan and its metabolites

    Maximum observed plasma concentration for bosentan and its metabolites was directly derived from their respective plasma concentration-time curves.

    Time frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose

  2. Time to reach the maximum plasma concentration (tmax) of bosentan and its metabolites

    Time frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose

  3. Area under the plasma concentration-time curve during a dose interval (AUCt) for the metabolites of bosentan

    AUCt was assessed at steady state (i.e., after at least 2 weeks of treatment with a same dose of the study drug) over 12 hours.

    Time frame: At pre-dose and 0.5h, 1h, 3h, 7.5h, and 12h post-dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jais X, Schulze-Neick I, Galie N, Morganti A, Dingemanse J, Kusic-Pajic A, Berger RM. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009 Dec;68(6):948-55. doi: 10.1111/j.1365-2125.2009.03532.x. PubMed 20002090 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Dec 2006 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2006
First posted
Apr 27, 2006
Start
May 2005
Primary completionActual
Dec 2006
CompletionActual
Feb 2007
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00319267
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
May 2005
Primary completion
Dec 2006
Completion
Feb 2007
Last update
Feb 3, 2025
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion